Icon (NASDAQ:ICLR) had its price objective raised by Robert W. Baird from $154.00 to $157.00 in a research note released on Tuesday morning. They currently have an outperform rating on the medical research company’s stock.

Other equities research analysts also recently issued reports about the stock. Jefferies Financial Group lifted their price target on shares of Icon to $150.00 and gave the stock a buy rating in a report on Friday, June 1st. BidaskClub upgraded shares of Icon from a hold rating to a buy rating in a report on Wednesday, May 23rd. Zacks Investment Research upgraded shares of Icon from a hold rating to a buy rating and set a $163.00 price target for the company in a report on Thursday, August 9th. SunTrust Banks lifted their price target on shares of Icon to $153.00 and gave the stock a buy rating in a report on Thursday, July 26th. Finally, Mizuho set a $146.00 price target on shares of Icon and gave the stock a hold rating in a report on Monday, August 6th. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The company has an average rating of Buy and an average price target of $146.22.

Shares of NASDAQ ICLR opened at $145.97 on Tuesday. The stock has a market cap of $8.01 billion, a PE ratio of 27.08, a PEG ratio of 2.12 and a beta of 0.35. Icon has a 12 month low of $101.22 and a 12 month high of $150.18. The company has a quick ratio of 2.10, a current ratio of 2.10 and a debt-to-equity ratio of 0.28.

Icon (NASDAQ:ICLR) last issued its quarterly earnings results on Wednesday, July 25th. The medical research company reported $1.31 EPS for the quarter, missing analysts’ consensus estimates of $1.48 by ($0.17). The firm had revenue of $641.60 million for the quarter, compared to analysts’ expectations of $618.64 million. Icon had a return on equity of 26.35% and a net margin of 13.69%. The business’s quarterly revenue was up 48.9% compared to the same quarter last year. During the same quarter last year, the firm earned $1.34 earnings per share. research analysts predict that Icon will post 6.08 earnings per share for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the stock. Fort L.P. purchased a new stake in Icon in the second quarter valued at approximately $121,000. Financial Gravity Wealth Inc. purchased a new stake in Icon in the first quarter valued at approximately $179,000. Gideon Capital Advisors Inc. purchased a new stake in Icon in the second quarter valued at approximately $203,000. HighPoint Advisor Group LLC purchased a new stake in Icon in the second quarter valued at approximately $203,000. Finally, Hilltop Holdings Inc. purchased a new stake in Icon in the second quarter valued at approximately $212,000. Hedge funds and other institutional investors own 87.96% of the company’s stock.

About Icon

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Read More: Book Value Per Share – BVPS

Analyst Recommendations for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.